Q-omics provides the consensus-scored USP31 profile across patient tissues and cancer cell-line models. USP31 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, USP31 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, USP31 RNA expression shows 20,238 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where USP31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP31 survival associations across molecular data types. USP31 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP31 RNA expression–survival associations across cancer types. High USP31 expression shows unfavorable associations in UVM, MESO, LGG and STAD, but favorable associations in BLCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for USP31 RNA expression.
This table summarizes USP31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP31 shows higher tumor expression in HNSC, KIRP, COAD, KIRC, LIHC and LUSC. The HNSC box plot shows higher USP31 RNA expression in tumor versus normal tissue (log2 FC = +1.106, t-test p < 0.001).
This table shows molecular features associated with USP31 in patient tissues and cancer cell lines. In patient samples, USP31 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
